Explore the intricate world of the immunosuppressive tumor microenvironment (TME), a key player in cancer progression and treatment resistance

Unpacking the potential of combining immuno-oncology and chemotherapy: understanding benefits, real-world impact, and addressing concerns.

Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery.

The importance of validating hypotheses, understanding the biology of cancer progression, and utilising biomarkers in early screening to stratify populations and improve clinical endpoints.

Unveiling advancements in preclinical immuno-oncology: Exploring humanized mouse models and human knock-in mice for targeted cancer therapies.

Looking at the past, present, and future of cancer vaccines. What are the reasons for past failings? And what's the next step for their development?

Developing and validating IO biomarkers present challenges, such as working with challenging sample types, interpreting sequencing data, and integrating new technologies into the clinic.

Insights on antigen-specific immunotherapy and the immunomodulatory functions of therapeutic chaperones at Immuno UK 2022.

Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development.

Our panel discussing combination therapeutics addresses challenges, modelling, and the importance of biomarkers.

Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field

Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?

The panel at Immuno UK 2022 discuss the unique challenges that come with delivering immunotherapies to solid malignancies.

As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.

The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME.

Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.

Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19.

Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.

The targeted cancer therapy has made recent clinical and market breakthroughs, but what are the next hurdles for ADCs?

Cell UK 2021 hosts experts in cell and immunotherapy working towards new diagnostic tools and therapies.